期刊文献+

贝利尤单抗治疗系统性红斑狼疮的有效性和安全性分析

Efficacy and Safety Analysis of Beliuzumab in the Treatment of Systemic Lupus Erythematosus
原文传递
导出
摘要 目的探究贝利尤单抗治疗系统性红斑狼疮(SLE)的效果.方法选取2020年1月—2022年12月建湖县人民医院收治的60例SLE患者为研究对象,根据随机数字表法将其分为对照组和观察组,每组30例.对照组采用泼尼松联合硫酸羟氯喹治疗,观察组在此基础上采用贝利尤单抗治疗.对比两组患者的治疗效果.结果观察组的治疗总有效率为93.33%,高于对照组的70.00%,差异有统计学意义(P<0.05).观察组的不良反应发生率为10.00%,低于对照组的33.33%,差异有统计学意义(P<0.05).治疗后,观察组的红细胞沉降率、C反应蛋白、免疫球蛋白G、24 h尿蛋白定量、抗双链DNA抗体定量、抗核抗体定量、抗核小体抗体定量水平均低于对照组,补体3、补体4、血小板计数水平均高于对照组,组间差异有统计学意义(P<0.05).结论采用贝利尤单抗治疗SLE的效果理想,能够提高疗效,有效控制病情,且用药后不良反应较少,值得临床推广使用. Objective To investigate the effect of beliuzumab in the treatment of systemic lupus erythematosus(SLE).Methods 60 SLE patients admitted to Jianhu County People's Hospital from January 2020 to December 2022 were selected as the research objects and were divided into a control group and an observation group according to random number table method,with 30 cases in each group.The control group was treated with prednisone combined with hydroxychloroquine sulfate,and the observation group was treated with beliuzumab on this basis.The therapeutic effects of the two groups were compared.Results The total effective rate of the observation group was 93.33%,higher than 70.00%of the control group,the difference was statistically significant(P<0.05).The incidence of adverse reactions in the observation group was 10.00%,lower than 33.33%in the control group,and the difference was statistically significant(P<0.05).After treatment,the levels of erythrocyte sedimentation rate,C-reactive protein,immunoglobulin G,24 hours urinary protein,anti-double-stranded DNA antibody,anti-nuclear antibody and anti-nucleosome antibody in the observation group were lower than those in the control group,and the levels of complement 3,complement 4 and platelet count were higher than those in the control group,the differences between the groups were statistically significant(P<0.05).Conclusion The effect of beliuzumab in the treatment of SLE is ideal,which can improve the curative effect and effectively control the disease,and the adverse reactions after medication are less,which is worthy of clinical promotion.
作者 尤新新 YOU Xinxin(Department of Rheumatology and Immunology,Jianhu County People's Hospital,Yancheng Jiangsu,224700,China)
出处 《反射疗法与康复医学》 2024年第5期173-176,共4页 Reflexology And Rehabilitation Medicine
关键词 贝利尤单抗 系统性红斑狼疮 有效性 安全性 Belizumab Systemic lupus erythematosus Effectiveness Security
  • 相关文献

参考文献9

二级参考文献87

  • 1张奉春,周滨,董怡.补体C1q及抗C1q抗体在狼疮肾炎发病机制中的作用[J].中华医学杂志,2005,85(14):955-959. 被引量:18
  • 2周滨,张奉春,董怡.补体C1q及抗C1q抗体与系统性红斑狼疮及狼疮肾炎相关性的研究[J].中华风湿病学杂志,2005,9(12):725-728. 被引量:23
  • 3杨其莲,卢静,张瑞雯,李端,力弘.艾司氟比洛芬凝胶抗炎镇痛作用的药效学研究[J].中国新药与临床杂志,2006,25(4):266-269. 被引量:9
  • 4Coornaert B,Carpentier I,Beyaert R.A20:central gate keeper in in?ammation and immunity[J].J Biol Chem,2009,284(13):8217-8221. 被引量:1
  • 5Schmitz R,Hansmann ml,Bohle V,et al.TNFAIP3(A20)is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma[J].J Exp Med,2009,206(5):981-989. 被引量:1
  • 6Kato M,Sanada M,Kato I,et al.Frequent inactivation of A20 in Bcell lymphomas[J].Nature,2009,459(7247):712-716. 被引量:1
  • 7Oshima S,Turer EE,Callahan JA,et al.ABIN-1 is a ubiquitin sensor that restricts cell death and sustains embryonic development[J].Nature,2009,457(7231):906-909. 被引量:1
  • 8Compagno M,Lim WK,Grunn A,etal.Mutations of multiple gene s cause deregulation of NF-kappa B in diffuse large B-cell lymphoma[J].Nature,2009,459(7247):712-721. 被引量:1
  • 9Jrvinen TM,Hellquist A,Zucchelli M,et al.Replication of GWASidentified systemic lupus erythematosus susceptibility genes affirms B-cell receptor pathway signalling and strengthens the role of IRF5in disease susceptibility in a Northern European population[J].Rheumatology(Oxford),2012,51(1):87-92. 被引量:1
  • 10Zhong H,Li XL,Li M,et al.Replicated associations of TNFAIP3,TNIP1 and ETS1 with systemic lupus erythematosus in a southwestern Chinese population[J].Arthritis Res Ther,2011,13(6):R186. 被引量:1

共引文献418

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部